At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
dexamethasone +8 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Autologous Transplant Followed by Consolidation and Maintenance for Participants ≥ 65 Years of Age Diagnosed With Multiple Myeloma or a Related Plasma Cell Malignancy
In Brief
A Phase 2 clinical trial evaluating dexamethasone, cisplatin, and 7 other interventions for Extramedullary Plasmacytoma and 6 related conditions. Completed, enrolled 41 participants across 1 site.
Detailed Summary
This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as primarily measured by progression-free survival, versus non-transplant approaches.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedMay 2013
Primary CompletionSep 2020
TodayJul 2026
First PostedMay 9, 2013
Enrollment StartApr 4, 2013
Primary CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 13.1 years ago
Interventions
dexamethasonedrug
Given PO
cisplatindrug
Given IV
doxorubicindrug
Given IV
cyclophosphamidedrug
Given IV or PO
etoposidedrug
Given IV
bortezomibdrug
Given IV
thalidomidedrug
Given PO
melphalandrug
Given IV
autologous stem cell transplantprocedure